Ensign Peak Advisors
SUPN icon

Ensign Peak Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Ensign Peak Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234K Sell
5,040
-150
-3% -$7.2K ﹤0.01% 1296
2026
Q1 		$268K Hold
5,190
– – ﹤0.01% 1168
2025
Q4 		$258K Sell
5,190
-9,850
-65% -$479K ﹤0.01% 1189
2025
Q3 		$719K Sell
15,040
-9,850
-40% -$397K ﹤0.01% 1211
2025
Q2 		$785K Hold
24,890
– – ﹤0.01% 1386
2025
Q1 		$815K Hold
24,890
– – ﹤0.01% 1363
2024
Q4 		$900K Hold
24,890
– – ﹤0.01% 1384
2024
Q3 		$776K Hold
24,890
– – ﹤0.01% 1460
2024
Q2 		$666K Hold
24,890
– – ﹤0.01% 1513
2024
Q1 		$849K Sell
24,890
-1,256
-5% -$37.4K ﹤0.01% 1422
2023
Q4 		$757K Hold
26,146
– – ﹤0.01% 1529
2023
Q3 		$721K Hold
26,146
– – ﹤0.01% 1435
2023
Q2 		$786K Hold
26,146
– – ﹤0.01% 1435
2023
Q1 		$947K Hold
26,146
– – ﹤0.01% 1284
2022
Q4 		$933K Buy
26,146
+6,800
+35% +$236K ﹤0.01% 1217
2022
Q3 		$655K Hold
19,346
– – ﹤0.01% 1318
2022
Q2 		$559K Hold
19,346
– – ﹤0.01% 1415
2022
Q1 		$625K Hold
19,346
– – ﹤0.01% 1457
2021
Q4 		$564K Sell
19,346
-30,740
-61% -$933K ﹤0.01% 1584
2021
Q3 		$1.34M Hold
50,086
– – ﹤0.01% 1312
2021
Q2 		$1.54M Hold
50,086
– – ﹤0.01% 1252
2021
Q1 		$1.31M Hold
50,086
– – ﹤0.01% 1312
2020
Q4 		$1.26M Sell
50,086
-2,400
-5% -$51.7K ﹤0.01% 1299
2020
Q3 		$1.09M Hold
52,486
– – ﹤0.01% 1272
2020
Q2 		$1.25M Hold
52,486
– – ﹤0.01% 1200
2020
Q1 		$944K Buy
52,486
+900
+2% +$18.9K ﹤0.01% 1192
2019
Q4 		$1.22M Buy
+51,586
New +$1.25M ﹤0.01% 1259

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Ensign Peak Advisors's SUPN Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 2.9% in Q2 2026, selling an estimated $7.2K and leaving 5,040 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #1296.

Ensign Peak Advisors first reported a position in SUPN in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.54M in Q2 2021. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Ensign Peak Advisors held 5,040 shares of Supernus Pharmaceuticals worth $234K as of Q2 2026.
  • Ensign Peak Advisors sold 150 Supernus Pharmaceuticals shares in Q2 2026, an estimated $7.2K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1296 holding.
  • Ensign Peak Advisors first reported a position in Supernus Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Supernus Pharmaceuticals position peaked at $1.54M in Q2 2021.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.